Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Robot researcher combines nature to nurture 'superhuman' navigation

  • Risks of opioids outweigh benefits for headache, low back pain, other conditions

  • Low social support linked to poor health in young heart attack survivors

  • EEG's potential to reveal depolarizations following TBI

  • To improve oral health of adults with developmental disabilities, improve support for caregivers

  • Gene interacts with stress, leads to heart disease in some people

  • Omega-3 fatty acids may prevent some forms of depression

  • Power can corrupt even the honest

  • Keeping your eyes on the prize can help with exercise, study finds

  • Predicting future course of psychotic illness

  •